早期非小细胞肺癌立体定向消融放疗后优化影像监测:国际德尔菲共识研究
该国际德尔菲共识研究邀请31名胸部放疗与影像专家,11名参与(9名放疗科医生、2名放射科医生),经3轮德尔菲流程、以≥75%同意/不同意阈值得出共识。共识推荐SABR后常规胸部CT随访,第1年3、6、12个月,第2年每6个月,第3–5年每年,5年后继续但频率未达共识;疑似局部复发时强烈推荐FDG PET/CT。
要点
- SABR后常规胸部CT随访,第1年3、6、12个月,第2年每6个月,第3–5年每年。
- 疑似局部复发时强烈推荐FDG PET/CT;不推荐6周时CT。
- RECIST 1.1不足以检测局部复发,应采用经验证的正式评分系统。
核心结论
- 该共识为早期非小细胞肺癌SABR后随访中不确定领域提供国际专家共识推荐。
研究设计与样本
- 邀请31名胸部放疗与影像国际意见领袖,11名接受参与(9名放疗科医生、2名放射科医生)。
- 采用3轮德尔菲流程,以5点Likert量表评分,预设≥75%同意/不同意阈值为共识。
主要发现
- 应答率100%,最终共识声明获所有参与者批准。
- 共识推荐SABR后常规胸部CT随访,第1年3、6、12个月,第2年每6个月,第3–5年每年。
- 疑似局部复发时强烈推荐FDG PET/CT;否则常规FDG PET/CT证据有限。
- 不推荐6周时CT;5年后应继续CT但频率未达共识。
- RECIST 1.1不足以检测局部复发,应采用经验证数据的正式评分系统分类高危影像特征。
关键数值与推荐
- 共识阈值:≥75%同意/不同意。
- CT随访时间:第1年3、6、12个月,第2年每6个月,第3–5年每年。
- 疑似局部复发的CT征象包括:侵犯邻近结构、边缘膨隆、持续增长、肿块样生长、球形生长、头尾方向生长、空气支气管征消失。
- 影像高度可疑且活检不安全/不可行或活检无诊断结果时,可无需病理证实复发即行挽救治疗。
临床怎么用
- SABR后按共识时间表行常规胸部CT随访,疑似局部复发时行FDG PET/CT。
- 采用正式评分系统评估高危影像特征,不单独依赖RECIST 1.1。
- 影像高度可疑且活检不可行时,可考虑无需病理证实行挽救治疗。
局限性
- 参与专家仅11名(9名放疗科医生、2名放射科医生),样本量小。
- 5年后CT随访频率未达成共识。
- 常规FDG PET/CT使用的证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Imaging after stereotactic ablative radiation therapy (SABR) for early-stage non-small cell lung cancer can detect recurrences and second primary lung cancers; however, the optimal follow-up practice of these patients remains unclear. We sought to establish consensus recommendations for surveillance after SABR. METHODS AND MATERIALS: International opinion leaders in thoracic radiation oncology and radiology were invited to participate (n = 31), with 11 accepting (9 radiation oncologists, 2 radiologists). Consensus-building was achieved using a 3-round Delphi process. Participants rated their agreement/disagreement with statements using a 5-point Likert scale. An a priori threshold of ≥75% agreement/disagreement was required for consensus. RESULTS: A 100% response rate was achieved and final consensus statements were approved by all participants. The consensus statements were: (1.1) thoracic computed tomography (CT) scans should be ordered routinely in follow-up; (1.2) if there is a suspicion for local recurrence (LR), fludeoxyglucose positron emission tomography/CT scans are strongly recommended. Otherwise, there is limited evidence to guide routine use of fludeoxyglucose positron emission tomography /CT; (1.3) CT imaging is not recommended at 6 weeks, but is recommended at months 3, 6, and 12 in year 1 and then every 6 months in year 2 and annually in years 3 through 5; (1.4) after 5 years, CT imaging should continue, although no consensus was reached regarding the frequency. (2.1) Response Evaluation Criteria in Solid Tumors 1.1 criteria are not sufficient for detecting LR; (2.2) a formal scoring system, informed by validated data, should be used to classify high-risk imaging features predictive of LR; (2.3) CT findings suspicious for LR include: infiltration into adjacent structures, bulging margins, sustained growth, mass-like growth, spherical growth, craniocaudal growth, and loss of air bronchograms. (3) Salvage therapy without pathologic confirmation of recurrence is acceptable if imaging findings are highly suspicious and a biopsy is not safe/feasible or if an attempted biopsy was nondiagnostic. CONCLUSIONS: These guidelines provide international expert consensus on areas of uncertainty in the management of early-stage non-small cell lung cancer patients after SABR.
引用
- Nguyen TK, Senan S, Bradley JD, et al. Optimal imaging surveillance after stereotactic ablative radiation therapy for early-stage non-small cell lung cancer: Findings of an International Delphi Consensus Study. Pract Radiat Oncol. 2017. PMID: 29291965. doi:10.1016/j.prro.2017.10.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。